Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

This study tests whether adding eflornithine (a drug that blocks a growth-related enzyme) to temozolomide (a standard chemotherapy) can improve outcomes in patients with newly diagnosed glioblastoma (grade 4 brain cancer) or certain grade 3 astrocytomas, after completing radiation therapy. **You may be eligible if...** - You have been diagnosed with grade 4 glioblastoma (IDH-wildtype) or grade 3 IDH-mutant astrocytoma - You have already completed radiation therapy with temozolomide (for GBM) or at least 2–4 cycles of adjuvant temozolomide (for astrocytoma) - Your blood counts and organ function are adequate - You are willing to use contraception **You may NOT be eligible if...** - You have had prior chemotherapy other than temozolomide - You have had prior Optune (electric field device) treatment - You have an active serious infection or cardiac disease within 6 months - You have poorly controlled diabetes or seizures - You used another investigational drug within 30 days Talk to your doctor to see if this trial is right for you.